Anti-CD19 CAR-T Cells therapy (Unc Lineberger Comprehensive Cancer Center)

N/A

Report date: 2025/09/20 20:00:09

Base Information

Drug NameAnti-CD19 CAR-T Cells therapy (Unc Lineberger Comprehensive Cancer Center)
Drug Alias NameiC9-CAR19 T cells therapy (Unc Lineberger Comprehensive Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursImmunoproliferative DisordersImmune System Diseases +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsImmunoproliferative DisordersLymphatic DiseasesLymphoma, B-Cell
Inactive IndicationsSolid tumoursImmune System DiseasesHematologic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A